Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Potently Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Wafaa B. Alsoussi, Jackson S. Turner, James Brett Case, et al.
The Journal of Immunology (2020) Vol. 205, Iss. 4, pp. 915-922
Open Access | Times Cited: 209

Showing 51-75 of 209 citing articles:

SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
Michael Diamond, Rita Chen, Xuping Xie, et al.
Research Square (Research Square) (2021)
Open Access | Times Cited: 86
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
Arturo Casadevall, Liise‐anne Pirofski, Michael J. Joyner
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 77
SARS-CoV-2 antibodies, serum inflammatory biomarkers and clinical severity of hospitalized COVID-19 patients
Roberto Gozalbo‐Rovira, Estela Giménez, Víctor Latorre, et al.
Journal of Clinical Virology (2020) Vol. 131, pp. 104611-104611
Open Access | Times Cited: 69
Animal models for SARS-CoV-2
Chung-Young Lee, Anice C. Lowen
Current Opinion in Virology (2021) Vol. 48, pp. 73-81
Open Access | Times Cited: 65
A vaccine-induced public antibody protects against SARS-CoV-2 and emerging variants
Aaron J. Schmitz, Jackson S. Turner, Zhuoming Liu, et al.
Immunity (2021) Vol. 54, Iss. 9, pp. 2159-2166.e6
Open Access | Times Cited: 63
Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody
Ronit Rosenfeld, Tal Noy-Porat, Adva Mechaly, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 59
Challenges and developments in universal vaccine design against SARS-CoV-2 variants
Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 56
Follicular T cells optimize the germinal center response to SARS-CoV-2 protein vaccination in mice
Cecília B. Cavazzoni, Benjamin L. Hanson, Manuel Alfredo Podestà, et al.
Cell Reports (2022) Vol. 38, Iss. 8, pp. 110399-110399
Open Access | Times Cited: 45
Immunosenescence and inflamm-ageing in COVID-19
Mohammad Reza Zinatizadeh, Peyman Kheirandish Zarandi, Mohsen Ghiasi, et al.
Ageing Research Reviews (2022) Vol. 84, pp. 101818-101818
Open Access | Times Cited: 39
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Caroline Hirsch, Yun Soo Park, Vanessa Piechotta, et al.
Cochrane library (2022) Vol. 2022, Iss. 6
Open Access | Times Cited: 38
Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19
Ting Lu, Rui Ma, Wenjuan Dong, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 37
Leveraging vaccination-induced protective antibodies to define conserved epitopes on influenza N2 neuraminidase
Ruipeng Lei, Wooseob Kim, Huibin Lv, et al.
Immunity (2023) Vol. 56, Iss. 11, pp. 2621-2634.e6
Closed Access | Times Cited: 22
Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds
Philip L. Tzou, Kaiming Tao, Janin Nouhin, et al.
Viruses (2020) Vol. 12, Iss. 9, pp. 1006-1006
Open Access | Times Cited: 68
Functional SARS-CoV-2-specific immune memory persists after mild COVID-19
Lauren B. Rodda, Jason Netland, Laila Shehata, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 63
Global SNP analysis of 11,183 SARS‐CoV‐2 strains reveals high genetic diversity
Fangfeng Yuan, Liping Wang, Yīng Fāng, et al.
Transboundary and Emerging Diseases (2020) Vol. 68, Iss. 6, pp. 3288-3304
Open Access | Times Cited: 62
Human Basigin (CD147) Does Not Directly Interact with SARS-CoV-2 Spike Glycoprotein
Robert J. Ragotte, David Pulido, Francesca R. Donnellan, et al.
mSphere (2021) Vol. 6, Iss. 4
Open Access | Times Cited: 54
On the road to ending the COVID-19 pandemic: Are we there yet?
James Brett Case, Emma S. Winkler, John M. Errico, et al.
Virology (2021) Vol. 557, pp. 70-85
Open Access | Times Cited: 51
Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection
Sandro Halwe, Alexandra Kupke, Kanika Vanshylla, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1498-1498
Open Access | Times Cited: 48
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Naveenchandra Suryadevara, Swathi Shrihari, Pavlo Gilchuk, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 46
Directed evolution of potent neutralizing nanobodies against SARS-CoV-2 using CDR-swapping mutagenesis
Jennifer M. Zupancic, Alec A. Desai, John S. Schardt, et al.
Cell chemical biology (2021) Vol. 28, Iss. 9, pp. 1379-1388.e7
Open Access | Times Cited: 40
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
William R. Strohl, Zhiqiang Ku, Zhiqiang An, et al.
BioDrugs (2022) Vol. 36, Iss. 3, pp. 231-323
Open Access | Times Cited: 32
SARS-CoV-2 Omicron boosting induces de novo B cell response in humans
Wafaa B. Alsoussi, Sameer Kumar Malladi, Julian Q. Zhou, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 29
A pandemic-enabled comparison of discovery platforms demonstrates a naïve antibody library can match the best immune-sourced antibodies
Fortunato Ferrara, M. Frank Erasmus, Sara D’Angelo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 28
Elicitation of potent SARS-CoV-2 neutralizing antibody responses through immunization with a versatile adenovirus-inspired multimerization platform
Christopher Chevillard, Axelle Amen, Solène Besson, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1913-1925
Open Access | Times Cited: 28
Mouse models of COVID-19 recapitulate inflammatory pathways rather than gene expression
Cameron Bishop, Troy Dumenil, Daniel J. Rawle, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 9, pp. e1010867-e1010867
Open Access | Times Cited: 27

Scroll to top